Related Experiment Video
Updated: Jan 12, 2026
Bone Marrow Sampling and Transplants
Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis
Jide Wang1, Yi Yang, Harry H X Xia
1Institute for Digestive Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Background And Aims:
FHL2 (4-1/2 LIM protein 2) is an adapter and modifier in protein interactions that is expressed mainly in the heart and ovary. It functions in a cell type- or promoter-specific manner. The aims of this study were to examine its expression in gastrointestinal cancers and to determine its role in cell differentiation and tumorigenesis.
Methods:
FHL2 expression in cancerous and normal gastrointestinal cells was detected by reverse-transcription polymerase chain reaction, immunoblotting, and immunohistochemistry. The effect of FHL2 suppression by both antisense and siRNA methods on cell differentiation and growth were evaluated in vitro and in vivo.
Results:
FHL2 expression was up-regulated in gastrointestinal cancer, compared with matched normal tissues. Stable transfection of gastric cancer cell line, AGS, and colon cancer cell line, Lovo, with antisense FHL2 induced lengthened or shuttle-shape morphologic changes with long or dendritic-like cytoplasmic processes and decreased the nuclear:cytoplasmic ratio. FHL2 antisense induced expressions of carcinoembryonic antigen and E-cadherin and the maturation of F-actin. Furthermore, FHL2 antisense inhibited the transcriptions of some oncogenes including cox-2, survivin, c-jun, and hTERT, and suppressed the promoter activity of activator protein-1 and hTERT. Suppression of FHL2 inhibited serum-dependent, anchorage-dependent and -independent cell growth, and suppressed de novo tumor formation in nude mice xenograft.
Conclusions:
Suppression of FHL2 induces cell differentiation and inhibits tumorigenesis. Antisense or siRNA methods targeting FHL2 is a promising strategy for treatment of gastrointestinal cancers.
Insights
Suppression of FHL2 (4-1/2 LIM protein 2) in gastrointestinal cancers promotes cell differentiation and inhibits tumor growth. Targeting FHL2 with antisense or siRNA offers a potential therapeutic strategy for these cancers.
Area of Science:
- Molecular biology
- Oncology
- Gastroenterology
Background:
- FHL2 (4-1/2 LIM protein 2) is an adapter protein primarily expressed in the heart and ovary.
- Its function is context-dependent, varying by cell type and promoter.
- This study investigates FHL2 in gastrointestinal cancers.
Purpose of the Study:
- To examine FHL2 expression in gastrointestinal cancers.
- To determine the role of FHL2 in gastrointestinal cancer cell differentiation.
- To elucidate FHL2's involvement in tumorigenesis.
Main Methods:
- FHL2 expression analyzed via RT-PCR, immunoblotting, and immunohistochemistry.
- FHL2 suppression achieved using antisense and siRNA techniques.
- In vitro and in vivo models assessed cell differentiation, growth, and tumor formation.
Main Results:
- FHL2 expression is significantly upregulated in gastrointestinal cancers compared to normal tissues.
- FHL2 suppression induced differentiation in gastric (AGS) and colon (Lovo) cancer cells, altering morphology and increasing differentiation markers (CEA, E-cadherin, F-actin).
- FHL2 suppression inhibited oncogene transcription (cox-2, survivin, c-jun, hTERT), AP-1 and hTERT promoter activity, cell growth, and tumor formation in vivo.
Conclusions:
- FHL2 suppression effectively induces cell differentiation and inhibits tumorigenesis in gastrointestinal cancers.
- Targeting FHL2 using antisense or siRNA represents a promising therapeutic approach for gastrointestinal malignancies.
